Dividends Inside Welcome to Dividends Inside
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
NervGen Pharma Corp.
NGEN
$3.74 (+ $0.16 + 4.47%)
Last updated: Previous Close (2026-05-20)
About the Company
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics to enable nervous system repair following trauma and disease. Its lead candidate, NVG-291, a subcutaneously administered peptide, targets mechanisms that inhibit repair and is currently in the Phase 1b/2a CONNECT SCI Study for individuals with chronic spinal cord injury, showing potential in improving function, independence, and quality of life. The company is also advancing NVG-300, a next-generation candidate in preclinical evaluation for ischemic stroke, spinal cord injury, and amyotrophic lateral sclerosis. NervGen Pharma Corp. holds a licensing agreement with Case Western Reserve University for patented technology addressing nerve damage conditions. Operating in the biotechnology sector, it addresses significant unmet needs in neurotrauma and neurologic disorders like stroke and multiple sclerosis. Founded in 2017 and headquartered in Vancouver, Canada, NervGen Pharma Corp. pursues innovative pharmacologic approaches to transform treatment paradigms for these debilitating conditions.
Price History
Latest News for NGEN
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN”No action is required; all shareholders, including Canadian shareholders, will continue to maintain full trading access on Nasdaq VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurot
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President (SVP), Patient Advocacy and Clinical Affairs. “We are assembling a
NervGen Pharma to Participate at Upcoming Investor Conferences
VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Adam Rogers, MD, President and Chief Executive Officer of NervGen, and other members of the Company’s executive leadership team, are scheduled to participate
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Bill Adams will retire as Chief Financial Officer, effective March 15th, 2026. The Company has engaged a leading executive search firm to identify a successor
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence, and quality of life in chronic spinal cord injury VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spi
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced its Board of Directors has unanimously appointed Adam Rogers, MD, as President and Chief Executive Officer (CEO), effective immediately. Dr. Rogers will continue l